Fortress Biotech's subsidiary, Checkpoint Therapeutics, received FDA approval for UNLOXCYT, the first PD-L1 blocking antibody for treating advanced skin cancer in patients not eligible for surgery or radiation.
AI Assistant
FORTRESS BIOTECH INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.